NovoCure (NASDAQ:NVCR) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS

NovoCure (NASDAQ:NVCR) released its earnings results on Thursday. The medical equipment provider reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.14, FiscalAI reports. The business had revenue of $193.40 million during the quarter, compared to analysts’ expectations of $182.28 million. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.00%. The firm’s revenue was up 15.7% on a year-over-year basis. During the same period last year, the business earned ($0.33) earnings per share.

Here are the key takeaways from NovoCure’s conference call:

• Q3 net revenue rose 16% year over year to $193 million, driven by 19% growth in active patients, stronger Optune Gio performance, and contributions from Optune Lua and Optune Pax. The company raised its 2026 revenue guidance to $736 million–$743 million.
• Optune Gio active patients reached a record 4,729, up 11% year over year, while Optune Lua’s Japan launch gained momentum with 110 Japanese patients and $4 million in quarterly revenue. Management expects Japan to become NovoCure’s second-largest market behind the U.S.
• The Optune Pax launch faced significant U.S. headwinds after the introduction of daraxonrasib, with practices reportedly overwhelmed by reimbursement appeals and treatment-related skin irritation; Pax ended the quarter with 276 active patients and $3.7 million in revenue. NovoCure expects to rebuild momentum through improved commercial execution, NCCN guideline inclusion, and planned combination studies with KRAS inhibitors.
• Profitability metrics improved substantially, with adjusted EBITDA of $16 million versus negative $3 million a year earlier and updated full-year adjusted EBITDA guidance of $24 million–$34 million. Management cautioned that quarterly results may fluctuate, but said its next objective is cash-flow breakeven.
• The FDA is reviewing the Optune Mya application for brain metastases from non-small cell lung cancer, with a decision expected by year-end and a potential early-2027 launch. KEYNOTE-D58 enrollment remains on track for completion by year-end, supporting potential future GBM growth.

NovoCure Trading Down 3.8%

NVCR traded down $0.54 during trading on Thursday, reaching $13.63. 3,167,656 shares of the company’s stock were exchanged, compared to its average volume of 1,669,844. The stock has a market capitalization of $1.59 billion, a PE ratio of -10.43 and a beta of 0.99. The firm has a fifty day moving average price of $15.98 and a two-hundred day moving average price of $14.80. The company has a current ratio of 2.89, a quick ratio of 2.70 and a debt-to-equity ratio of 0.58. NovoCure has a one year low of $9.82 and a one year high of $21.45.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NVCR. HC Wainwright set a $32.00 price objective on NovoCure in a research note on Friday, July 24th. JPMorgan Chase & Co. began coverage on shares of NovoCure in a research note on Monday, July 13th. They set a “neutral” rating and a $17.00 target price for the company. Wall Street Zen lowered shares of NovoCure from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Zacks Research raised shares of NovoCure from a “strong sell” rating to a “hold” rating in a report on Friday, July 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NovoCure in a report on Thursday, August 27th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $21.20.

NovoCure Company Profile

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.